Form 4: United Therapeutics CEO Exercises Options, Sells Shares

United Therapeutics' Chairperson and CEO, Martine A. Rothblatt, exercised stock options and subsequently sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO and Director of United Therapeutics Corp (UTHR), executed transactions on March 26, 2026.
• Exercised 9,500 stock options at an exercise price of $146.03 per share.
• Sold a total of 9,500 shares of common stock in multiple transactions at weighted average prices ranging from $530.9494 to $539.98 per share.
• All transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, Ms. Rothblatt directly beneficially owns 40,513 shares of common stock and 59,500 stock options.
• Indirect beneficial ownership includes 166 shares by spouse, 324,518 shares by family trusts where the reporting person shares investment power, 258,117 shares by family trusts where the spouse is sole trustee/beneficiary or co-trustee/settlor, 45,596 shares by family trusts where the spouse shares investment power, and 10,962 shares by family trusts where the reporting person is sole trustee/beneficiary or co-trustee/settlor.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and personal financial management, with no direct positive or negative implications for the company's operational performance or strategic direction.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned approach to managing executive compensation and personal finances rather than a reaction to recent market events.
• The exercise price of the options ($146.03) is significantly lower than the sale prices (ranging from $530.9494 to $539.98), demonstrating a substantial gain from the exercised options.

Negatives

• The sale of shares by a high-ranking insider, even if pre-arranged, can sometimes be perceived negatively by some investors, although it is a common practice for liquidity and diversification.

Risks

• NA

Future Outlook

The pre-arranged 10b5-1 trading plan is set to continue until the earlier of the exercise of 1,734,410 stock options (which expire on March 17, 2027) or December 31, 2026, indicating further planned transactions by the reporting person in the future.

Industry Context

StockSavvy.ai notes that routine insider transactions under 10b5-1 plans are common among executives for personal financial planning, diversification, and liquidity management. These pre-scheduled trades generally do not signal a change in company fundamentals or management's long-term outlook for United Therapeutics within the biotechnology and pharmaceutical industry.

Comparison to Industry Standards

• Routine 10b5-1 plan transactions, such as those reported by Martine A. Rothblatt, are standard practice for executives in publicly traded companies across various industries, including the biotech and pharmaceutical sectors.
• These plans allow insiders to sell shares at predetermined times or prices, mitigating concerns about insider trading based on material non-public information.
• No specific comparable companies, projects, or results are detailed in the filing to allow for a direct performance comparison.

Related Party Transactions

• Indirect beneficial ownership includes 166 shares held by spouse.
• Indirect beneficial ownership includes 324,518 shares held in family trusts where the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
• Indirect beneficial ownership includes 258,117 shares held in family trusts where the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
• Indirect beneficial ownership includes 45,596 shares held in family trusts where the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
• Indirect beneficial ownership includes 10,962 shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine insider transactions executed under a pre-arranged plan.
• The transactions primarily affect the personal liquidity and diversification of the reporting person.

Next Steps

• The 10b5-1 plan will continue until the earlier of the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, suggesting further planned transactions.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and personal financial planning and typically do not reflect a change in the company's fundamental outlook or warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment stance.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, CEO, Director